Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (August 2022)

44 slides from Marinus Pharmaceuticals's investor presentation, Aug 11, 2022

  1. Slide 1: Corporate Presentation August 2022

    NASDAQ: MRNS @ MarinusPharma Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation August 2022

  2. Slide 2: Forward-looking statements

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe

  3. Slide 3: Building Upon A Strong Foundation to Achieve Long-term Value Creation

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Building Upon A Strong Foundation and Differentiated Product Profile To Achieve Long - term Value Creation 3 Explore Unmet Medical Need in Rare Epilepsies and Acute Neurological Indications Strategic Collaborations Building Strong Commercial Infra

  4. Slide 4: Ganaxolone Development Pipeline

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 4 PDUFA date March 2022 MAA filing validation Q4 2021 Ph3 patient enrollment Q1 2022 Topline data 1H 2024 GANAXOLONE Phase 1 Phase 2 Phase 3 Approved Oral Suspension Intravenous Intravenous Intravenous Oral Suspensi

  5. Slide 5: Ganaxolone U.S. Market Opportunity

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 5 ¹ Symonds JD 2019 Brain ² Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657 – 68. ³DeLorenzo RJ et al. J Clin Neurophysiol .. 1995; 12: 316 - 325 4 Kapur et al. N Engl J Med 2019;381:2103 - 13 5 Rossetti and Lowenste

  6. Slide 6: Marigold Phase 3 Data in CDKL5 Deficiency Disorder

    Marigold Phase 3 Data in CDKL5 Deficiency Disorder

  7. Slide 7: Phase 3 Marigold Trial Achieved Primary Efficacy Endpoint in Seizure Reduction

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 7 Phase 3 Marigold Trial In CDKL5 Deficiency Disorder Achieved Primary Efficacy Endpoint in Seizure Reduction Ganaxolone Placebo 0 10 20 30 40 Median Percent Reduction 28-day Frequency of Major Motor Seizures 30.7% 6.9% *Wilcoxon Rank-Sum Test **H

  8. Slide 8: Marigold Open-label Extension Data

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I ► At the time of the analysis, 54 patients (61.4%) were still in the OLE study ► Median percent reductions in MMSF from baseline ranged 25% to 42% during initial 12 months and was between 44% and 56% through 24 months in the OLE phase • Open - lab

  9. Slide 9: ZTALMY Commercial Launch in CDKL5 Deficiency Disorder

    ZTALMY ® ( Ganaxolone ) Oral Suspension CV Commercial Launch in CDKL5 Deficiency Disorder (CDD) First FDA - approved treatment for seizures associated with CDD in patients 2 and older Can Now Be Prescribed Facilitating access with ongoing prescription support and education Ongoing Patient Support In

  10. Slide 10: Early Progress Indicators Following July Commercial Launch

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Early Progress Indicators Following July 28 Commercial Launch 10 Encouraging initial volume of prescriptions and enrollment forms Majority of prescriptions are for new patients not previously treated w ZTALMY Expanded Access Program transition pla

  11. Slide 11: ZTALMY U.S. Market Opportunity

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY U.S. Market Opportunity 11 ~2,000 Addressable Pediatric Patients * Several data points suggest additional market opportunity in adult population 1 Symonds JD 2019 Brain *Estimated based on Symonds JD 2019 Brain Weight - based pricing Bottle

  12. Slide 12: Rare Epilepsies Oral Ganaxolone Pipeline

    Rare Epilepsies Oral Ganaxolone Pipeline

  13. Slide 13: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments” - Kari Luther Rosbeck, President &

  14. Slide 14: Tuberous Sclerosis Complex (TSC)

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 14 Tuberous Sclerosis Complex (TSC) 1 diMichele, et al, J. Neuro Neurosurg Psychiatry, 2003 *Failure of two prior antiseizure medications with ongoing, frequent seizures. CAUSE • Defect or mutation of TSC1 and/or TSC2 genes SYMPTOMS • Benign tumor

  15. Slide 15: TSC Phase 2 Trial Results

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 15 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 Percent reduction in TSC-associated seizure frequency =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 16.6% median reduction in TSC - associated

  16. Slide 16: Phase 2 Protocol Refinements Informed by Phase 3

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 16 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy 0 7 14 21 28 35 0 20 40 60 80 100 Time (days) Approx. % Max GNX Dose TSC Ph2 Titration TSC Ph3 Titration

  17. Slide 17: Phase 3 Trial Overview

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Trial Overview 17 ► Enrollment: ~162 patients, targeting 80 sites, predominantly in the U.S., Western Europe, Canada and Israel ► Primary Endpoint: Percent change in TSC - associated seizure frequency ► Key Secondary Endpoints: Percent cha

  18. Slide 18: Second Generation Product Development

    Second Generation Product Development

  19. Slide 19: Second Generation Formulation Strategic Objectives

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Formulation 19 Strategic Objectives Enhanced Efficacy Achieve target blood levels to drive better clinical response Improved Safety Profile Optimize PK to mitigate somnolence levels Reduced Dosing Frequency More sustained serum l

  20. Slide 20: Second Generation Oral Ganaxolone Rationale and Phase 1 Overview

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Oral Ganaxolone Rationale and Phase 1 Overview 20 Cohort 1 / 2 Treatment Six crossover treatment periods separated by 4 - day washout SCREENING Day - 1 thru – 28d Day 1 - Day 25 FOLLOW UP CALL Day 32 +/ - 2d Cohort 1 / 2 (n=6) Ph

  21. Slide 21: Ganaxolone Second-Generation Oral Formulation

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Second - Generation Oral Formulation 21 However, AUC increases linearly throughout the range of doses administered *Data on file. Studies 1042 - 0402 and 1042 - 0404, 7 - day multiple ascending dose studies with ganaxolone capsule formu

  22. Slide 22: Pathways to a Novel Oral Formulation for Lennox-Gastaut Syndrome

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Development plan goals • Efficiently select next generation product for clinical development in LGS and other potential indications • Proceed with targeted investments in parallel formulation and prodrug development to accelerate entry to Phase 2/

  23. Slide 23: Acute Seizure Disorders Intravenous (IV) Ganaxolone Pipeline

    Acute Seizure Disorders Intravenous (IV) Ganaxolone Pipeline

  24. Slide 24: Status Epilepticus

    Status Epilepticus

  25. Slide 25: Status Epilepticus (SE): Definition and Epidemiology

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus (SE): Definition and Epidemiology 25 SE is the second most common neurologic emergency in the U.S. 1 150,000 cases per year 2 1. Anesthesia and Intensive Care Medicine, February 02, 2018 , Update on the management of status epil

  26. Slide 26: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 26 Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain 1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes 2 EEG bispectral index in healthy volunteers fol

  27. Slide 27: Strategic Approach to SE Clinical Development

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Strategic Approach to SE Clinical Development 27 1. DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995; 12: 316 - 325 2. Kapur et al. Randomized Trial of Three Anticonvulsant Medications for St

  28. Slide 28: Refractory Status Epilepticus Trial (RSE) Design

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper 28 Phase 2 Refractory Status Epilepticus Trial (RSE) Design • Diagnosis of convulsive or non - convulsive SE • Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics

  29. Slide 29: Patient Demographics from Completed Phase 2 RSE Trial

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 29 Patient Demographics from Completed Phase 2 RSE Trial 8 males, 9 females Mean age: 57 years old (range: 23 - 88) 5 (29%) CSE, 11 (65%) NCSE, 1 (6%) CSE → NCSE 7 (41%) yes 10 (59%) no 17 patients enrolled Types of SE History of Epilepsy Mean # o

  30. Slide 30: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 30 Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Data presented at AES 2019 AEDs – antiepileptic drugs Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status - free throu

  31. Slide 31: PK/PD Relationship and Rationale for Target Dose

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 31 PK/PD Relationship and Rationale for Target Dose Modeled PK Curves for All Dose Groups High Dose Achieves Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduction (>80%) Throughout Entire Analysis Window Data presented

  32. Slide 32: RAISE: Phase 3 Trial in Refractory Status Epilepticus

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RAISE: Phase 3 Trial in Refractory Status Epilepticus 32 Ganaxolone development for RSE is being funded, in part, by the Biomedical Advanced Research and Development Authority (BARDA ), part of the Office of the Assistant Secretary for Preparednes

  33. Slide 33: RAISE Protocol Amended to Accelerate Enrollment

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RAISE Protocol Amended to Accelerate Enrollment 33 Protocol component Original Protocol Amended Protocol Escalation of treatment Patients excluded IF SE would NOT warrant anesthesia for the next 24 hours IV anesthesia would likely be next treatmen

  34. Slide 34: RESET: Phase 2 Trial in Established Status Epilepticus

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RESET: Phase 2 Trial in Established Status Epilepticus 34 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103 - 13. Key Trial points: • Patients with convulsive status epilepticus •

  35. Slide 35: RESET Trial Design in Established Status Epilepticus

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RESET Trial Design in Established Status Epilepticus 35 Screening <30 min Enrollment Fail BZD IV ganaxolone infusion 1 IV ganaxolone infusion 3 SOC IV AED Convulsive SE (N=40) Ganaxolone bolus Ganaxolone bolus Ganaxolone bolus Seizures YES NO Seiz

  36. Slide 36: RAISE II: Phase 3 Trial in Refractory Status Epilepticus

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RAISE II: Phase 3 Trial in Refractory Status Epilepticus 36 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103 - 13. Benzodiazepine Administered IV AEDs (antiepileptic drugs) IV An

  37. Slide 37: Building Commercial Infrastructure for Future IV Launches

    Building Commercial Infrastructure for Future IV Launches

  38. Slide 38: Clinical and Healthcare Costs Associated with RSE

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Clinical and Healthcare Costs Associated with RSE 38 Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (> 1 IV AED) Cohort 3 (≥ 1 IV anesthetic) All Unique RSE patient encounter, N (%) 14,694 (33.4) 10,140 (23.1) 19,154 (43.5) 43

  39. Slide 39: Differentiated Market Access Strategy for IV Ganaxolone

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Differentiated Market Access Strategy to Ensure Success for IV Ganaxolone Formulation 39 (DRG), diagnosis - related group reimbursement PRICING & REIMBURSEMENT • U.S./EU Pricing research initiated and ongoing • Determining New Technology Add - on

  40. Slide 40: Financial Update

    Financial Update

  41. Slide 41: Financial Overview: Q2 2022

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview: Q2 2022 41 Analyst Coverage*: Cantor Fitzgerald: Charles C. Duncan, Ph.D. Cowen: Joseph Thome, Ph.D. H.C. Wainwright & Co: Douglas Tsao Jefferies: Andrew Tsai JMP Securities: Jason N. Butler, Ph.D. Ladenburg Thalmann: Michael H

  42. Slide 42: Liquidity Overview

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Liquidity Overview 42 1 Lump sum payment of $110 million upon the closing of the transaction, which is subject to customary closing conditions and is ex pected to occur following the expiration of the applicable U.S. antitrust clearance requiremen

  43. Slide 43: Intellectual Property

    Intellectual Property

  44. Slide 44: Multiple Layers Of Potential Protection

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Multiple Layers Of Potential Protection 44 Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in U.S. and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in U.S. Paten

Marinus Pharmaceuticals — Investor Presentation (August 2022) on 6ix